主要原因系公司产品业务板块凭借显著的毛利率优势，随着收入规模的不断扩大，为公司利润贡献重要 增长支撑，这也充分体现了公司通过技术研发、生产工艺优化和市场快速响应等方面逐步提高运营效 率，公司产品亦获得了越来越多客户的认可。 奥浦迈(688293.SH)发布2025年度业绩预增公告，预计2025年年度实现归属于母公司所有者的净利润 4,200万元左右，与上年同期(法定披露数据)相比，预计将增加2,094.77万元左右，同比增加99.50%左 右。 ...

主要原因系公司产品业务板块凭借显著的毛利率优势，随着收入规模的不断扩大，为公司利润贡献重要 增长支撑，这也充分体现了公司通过技术研发、生产工艺优化和市场快速响应等方面逐步提高运营效 率，公司产品亦获得了越来越多客户的认可。 智通财经APP讯，奥浦迈(688293.SH)发布2025年度业绩预增公告，预计2025年年度实现归属于母公司 所有者的净利润4,200万元左右，与上年同期(法定披露数据)相比，预计将增加2,094.77万元左右，同比 增加99.50%左右。 ...

Core Viewpoint - Nearshore Protein (688137) expects a net loss attributable to shareholders of the parent company between 85 million and 66 million yuan for the fiscal year 2025, compared to a net loss of 54.4163 million yuan in the same period last year [1] Group 1: Financial Performance - The company anticipates an increase in main business revenue during the reporting period [1] - The increase in research and development expenses, as well as sales expenses, is noted [1] - Government subsidies have decreased compared to the same period last year [1]

Core Viewpoint - Huaxi Biological expects a significant increase in net profit for 2025, driven by systematic transformation rather than short-term scale expansion [1][3] Financial Performance - The company anticipates a net profit attributable to shareholders of between 270 million to 320 million yuan, representing a year-on-year growth of 54.93% to 83.63% [1] - The net profit after deducting non-recurring gains and losses is projected to be between 167 million to 217 million yuan, with a year-on-year increase of 55.68% to 102.29% [1] Cost Management - Sales expenses are expected to decrease by over 30% in 2025 [3] - Management expenses are projected to decline by more than 10% year-on-year [3] Strategic Transformation - The company is transitioning from a scale-oriented approach to a quality and efficiency-oriented strategy, leading to a deep restructuring of its operational model [3] - Organizational management has been optimized by integrating overlapping functions and promoting a flatter, more agile structure to enhance decision-making efficiency [3] Research and Development - Huaxi Biological focuses on the key role of carbohydrates in cell differentiation and signaling mechanisms, with research centered on three core areas: extracellular matrix, intercellular communication, and intracellular processes [3] - The company is advancing original technology layouts and product transformations in the areas of aging intervention and tissue regeneration [3] AI Integration - The company is actively promoting the deep integration of AI with business scenarios, enhancing smart upgrades in R&D, manufacturing, supply chain management, and financial operations [3]

Group 1 - The company, Univi (301166), announced an expected net loss of 15 million to 30 million yuan for the year 2025 [1] - The net profit loss, excluding non-recurring gains and losses, is projected to be between 34.48 million and 49.48 million yuan [1]

Core Viewpoint - The report highlights that China's biopharmaceutical industry is transitioning from a "cost advantage" to "innovation-driven" growth, with overseas expansion becoming a second growth curve for innovative drug companies, indicating a shift from "heavy R&D" to "strong commercialization" [1][3]. Group 1: Industry Growth and Financial Performance - By the first three quarters of 2025, China's innovative drug sector revenue reached 48.83 billion yuan, reflecting a year-on-year growth of 22.1% [3]. - The total amount of foreign licensing for Chinese innovative drugs exceeded 100 billion USD in the first ten months of 2025, averaging nearly 300 million USD per day in international capital for Chinese original innovative drugs [3]. - Several companies have turned losses into profits, marking a period where the profitability of the Chinese biopharmaceutical industry is entering a realization phase [3]. Group 2: Evolution of Export Structure - The report outlines a significant transformation in China's biopharmaceutical exports, moving from low-value raw materials to high-value formulations, innovative drugs, and high-end medical devices [6][13]. - The overseas market strategy has diversified, focusing on consolidating developed markets while exploring emerging markets, with the U.S. remaining a primary target for innovative drugs [6][8]. Group 3: Outbound Strategies and Models - Chinese biopharmaceutical companies have developed a diverse set of outbound strategies, including independent expansion, co-development, licensing-out, NewCo models, and distribution agency, evolving from simple equity transactions to deeper participation in the global value chain [9][11]. - The limitations of traditional licensing-out models are becoming apparent, while Co-Co and NewCo models facilitate deeper involvement in global R&D, registration, and commercialization processes [9][11]. Group 4: Future Trends and Strategic Recommendations - The report identifies four key trends for 2026 and beyond: continuous evolution of technological frontiers, a shift from equity transactions to strategic symbiosis, the growing importance of emerging markets, and enhanced collaborative effects across the industry chain [14]. - Companies are encouraged to build long-term capabilities in compliance, commercialization, and brand image, moving from "industry outbound" to "global brand building" [17][18].

Core Viewpoint - The company, Haiwang Biological, anticipates a net loss attributable to shareholders of approximately 490 million to 600 million yuan for 2025, with basic earnings per share projected to be a loss of 0.1862 to 0.228 yuan. This is an improvement compared to the previous year's loss of about 1.193 billion yuan, or a loss of 0.4536 yuan per share. The primary reason for this performance change is the optimization of business structure, which has impacted short-term results [1]. Financial Performance - The expected net loss for 2025 is between 490 million and 600 million yuan, with basic earnings per share losses ranging from 0.1862 to 0.228 yuan [1]. - In the previous year, the company reported a net loss of approximately 1.193 billion yuan, with basic earnings per share losses of 0.4536 yuan [1]. Strategic Initiatives - The company aims to enhance sales gross margin, ensure asset safety, improve financing channels, and optimize capital returns as part of its management philosophy for 2025 [1]. - The focus will be on cash flow as the core element, with the goal of maximizing efficiency in all operational activities [1]. - The company is conducting a comprehensive evaluation of long-term loss-making subsidiaries or business segments that do not align with its core strategy, planning to divest poor assets through methods such as equity transfer, asset sales, and liquidation [1]. Operational Adjustments - Some subsidiaries have had their operations halted, which is expected to impact the net profit loss for the reporting period by approximately 110 million to 150 million yuan due to ongoing liquidation processes [1]. - Although these measures will affect the company's overall operational scale and profit contributions in the short term, they are intended to effectively optimize asset quality and cash flow, laying a solid foundation for the company's long-term healthy and steady development [1].

来源：扬州国金集团 每日｜荐读 热文： 谁押中了沐曦股份？ 荐读： 2025募资市场年度观察：一年聊过239家LP的真实感受 荐读： 2025年IPO退出盘点：哪些GP赚钱了？ 热文： 投资人"忙疯了" 2026年1月23日，爱博弘盛（扬州）股权投资基金合伙企业（有限合伙）完成工商登记，标志着 扬州市首支CVC生物医药产业子基金顺利落地。该基金由国信弘盛私募基金管理有限公司担任基 金管理人及执行事务合伙人，联合爱博医疗（688050.SH）、扬州市生物医药产业投资基金、广 陵区共同出资设立， 总认缴规模5亿元。 据悉，该基金未来将联合产业龙头与地方国资，以"产业+资本+券商资源"为核心模式，聚焦生物 医药赛道，开展专业化投资布局。 ...

Group 1 - The event "Unveiling the Banner and Leading the Energy, National Integration Starts a New Journey" was co-hosted by the Guangzhou Federation of Industry and Commerce and the Guangzhou State-owned Assets Supervision and Administration Commission, aimed at creating an efficient platform for cooperation between state-owned enterprises (SOEs) and private enterprises (PEs) [1][4] - The event focused on 12 "unveiling" demand projects from 10 key SOEs, aligning with the cooperation intentions of PEs, facilitating close communication between supply and demand sides [3][4] - Five key SOEs, including Guangzhou Pharmaceutical Group and Guangzhou Construction Group, presented specific demands in fields such as biomedicine, high-end equipment manufacturing, and artificial intelligence, while the remaining SOEs engaged in precise matching through on-site discussions [3][4] Group 2 - The private enterprise roadshow highlighted innovative companies like Guangzhou Lido Robot Intelligent Technology Group and Guangdong Yushun Digital Technology, showcasing their customized solutions and technical capabilities in niche areas [3] - Guangzhou Lido Robot presented its self-developed vacuum negative pressure climbing robot, emphasizing safety performance improvements and cost control solutions for high-rise building construction [3] - Guangdong Yushun Digital Technology focused on digital transformation needs of SOEs, offering comprehensive digital solutions and AI technology applications, which received broad recognition from SOE representatives [3][4] Group 3 - The event facilitated in-depth discussions between SOE and PE representatives, fostering a consensus on cooperation and creating a direct and efficient communication platform [4] - The organizers plan to establish a long-term mechanism for "demand release - precise matching - project implementation - follow-up service" to ensure continuous and effective cooperation between SOEs and PEs [4]

奥浦迈公告称，预计2025年度营收3.55亿元，同比增长19.43%；归母净利润4200.00万元，同比增加约 2094.77万元，增幅约99.50%；扣非净利润2100.00万元，同比增加约1441.41万元，增幅约218.86%。业 绩增长主因是产品业务板块毛利率高、收入规模扩大，且公司获高新技术企业资格，所得税税率由25% 降至15%，所得税费用减少约1100.00万元。不过，2025年公司计提资产减值损失约1912.81万元，对净 利润产生较大影响。 ...